Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
ADAPY Stock Chart & Stats
$0.05
-$0.04(-6.19%)
At close: 4:00 PM EST
$0.05
-$0.04(-6.19%)
Day’s Range― - ―
52-Week Range$0.02 - $0.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.65M
Market Cap
$10.34M
Enterprise ValueN/A
Total Cash (Recent Filing)$26.06M
Total Debt (Recent Filing)$48.68M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding265,051,600
10 Day Avg. Volume4,539,686
30 Day Avg. Volume50,649,310
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)11.47
Price to Sales (P/S)0.76
P/FCF Ratio-1.79
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset SaleAdaptimmune has agreed to sell key cell therapies to US WorldMeds for up to $85M, including a $55M upfront payment.
Expansion Of Treatment CentersThe company reported 16 invoiced patients in 2Q, and 30 authorized treatment centers now accepting referrals.
Revenue GrowthTecelra net product revenue for 2Q25 was $11.1M, above consensus estimate and grew ~178% from 1Q25.
Bears Say
Preclinical AssetsThe sale of key assets leaves the company with preclinical assets that are still in the early stages of development.
Stock DowngradeAdaptimmune's stock rating has been downgraded to Neutral from Buy due to the absence of significant near-term opportunities.
Workforce ReductionThe company announced plans to reduce its workforce by 62% as well as the departure of several C-suite executives.
Adaptimmune Therapeutics News
ADAPY FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.02 and its highest was $0.69 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Adaptimmune Therapeutics’s market cap is $10.34M.
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 89 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Currently, no data Available
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Overvalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 265,051,600 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Currently, no hedge funds are holding shares in ADAPY
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Technical Analysis
Mersana Therapeutics
―
BioAtla
―
LAVA Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
38.27% Insiders
0.13% Mutual Funds
7.53% Other Institutional Investors
54.07% Public Companies and
Individual Investors